A Phase 3 interventional study of Placebo and Brivaracetam in Partial Seizures With or Without Secondary Generalization and Epilepsy, sponsored by UCB Biopharma SRL. Completed at 94 sites in 7 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 6th largest by enrollment, is one of 3 that started in 2017, is one of 21 in phase 3, and was the 22nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2017.
This study's enrollment of 449 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 14th largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2017, is one of 74 in phase 3, and was the 108th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* 12 weeks Treatment Period: Subjects will receive Placebo * 4 weeks Down-Titration Period: Subjects will receive Placebo
Drug: Placebo
12 weeks Treatment Period: Subjects will receive BRV 50 mg/day \- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day \- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period
Drug: Placebo · Drug: Brivaracetam
12 weeks Treatment Period: Subjects will receive BRV 200 mg/day \- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day \- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period
Drug: Placebo · Drug: Brivaracetam
* Pharmaceutical form: Film-coated tablets * Route of administration: Oral use
* Pharmaceutical form: Film-coated tablets * Concentration: 25 mg tablets and 50 mg tablets * Route of administration: Oral use
Also known as: Briviact
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
Serious Adverse event (SAE) was defined as any events which: • results in death, • is life-threatening threatening (note that this did not include a reaction that might have caused death had it occurred in a more severe form.), •results in significant or persistent disability/incapacity, • results in a congenital anomaly/birth defect (including that occurring in a fetus), • results in Important medical event that, based upon appropriate medical judgment, may jeopardize the participant and might require medical or surgical intervention to prevent 1 of the other outcomes listed here, and • results in initial inpatient hospitalization or prolongation of hospitalization. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period
According to International League Against Epilepsy (ILAE) classification (1981), seizures were classified as type IA (IA1, IA2, IA3, and IA4), IB, IC, II (IIA, IIB, IIC, IID, IIE, and IIF) or III. 28 day adjusted seizure frequency for partial seizures (seizure types IA+IB+IC) was calculated for treatment period by dividing the number of partial seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.
Time frame: From Baseline to 12-week Treatment Period
50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
Responders were those participants with at least 50% reduction from Baseline to the 12-week Treatment Period in partial seizure frequency per 28 days. 50% Responder rate was calculated for treatment period by dividing the number of 50% responders by the number of participants in the analysis set and multiplying the resulting value by 100.
Time frame: From Baseline to 12-week Treatment Period
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency, and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline to the Treatment Period.
Time frame: From Baseline to 12-week Treatment Period
Percentage of Participants With Categorized Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
The percentage of participants within each of the following categories of percent change in partial seizure frequency from Baseline to the Treatment Period were summarized for each treatment group: 100%, 75% to less than 100%, 50% to less than 75%, 25% to less than 50%, -25% to less than 25%, and less than -25%. Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency.
Time frame: From Baseline to 12-week Treatment Period
All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period
There were three types of epileptic seizures: Partial epileptic seizures (Type I), Generalized epileptic seizures (Type II) and unclassified epileptic seizures (Type III). 28 day adjusted seizure frequency for all seizure types was calculated for treatment period by dividing the number of targeted seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.
Time frame: During the 12-week Treatment Period
Percentage of Participants Who Are Seizure Free (Partial, All Epileptic Seizures) During the 12-week Treatment Period
Participants were defined as seizure free, if they did not have missing diary days and no reported seizures during the Treatment Period.
Time frame: During the 12-week Treatment Period
Time to 1st Partial Seizure During the 12-week Treatment Period
The evaluation of time to 1st partial seizure was based on the relative day of occurrence of the 1st partial seizure during the Treatment Period.
Time frame: During the 12-week Treatment Period
Time to 5th Partial Seizure During the 12-week Treatment Period
The evaluation of time to 5th partial seizure was based on the relative day of occurrence of the 5th partial seizure during the Treatment Period.
Time frame: During the 12-week Treatment Period
Time to 10th Partial Seizure During the 12-week Treatment Period
The evaluation of time to 10th partial seizure was based on the relative day of occurrence of the 10th partial seizure during the Treatment Period.
Time frame: During the 12-week Treatment Period
Brivaracetam Plasma Concentration
Blood samples were collected at indicated time points for the 50mg/day and 200mg/day groups to determine the brivaracetam plasma concentration. Participants of arm 'BRV 200 mg/day' received BRV 200 mg/day until Week 12 only and 150 mg/day during the Transition Period at Week 14. Therefore, the data is reported according to the dosage information at specified time point. As per planned analysis, one blood sample was collected for BRV plasma levels during each dosing interval between 0 to 4 hours, 4 to 8 hours, and 8 to 12 hours postdose.
Time frame: Plasma samples were collected at >0-4hours, >4-8hours, >8hours in weeks 2, 4, 8, 12, and 14
The study started to enroll participants in August 2017 and concluded in June 2022.
| Milestone | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| Started | 149 | 152 | 148 | 0 | 0 | 0 |
| Started treatment period (12 weeks) | 149 | 152 | 148 | 0 | 0 | 0 |
| Started down-titration period (4 weeks) | 7 | 9 | 7 | 0 | 0 | 0 |
| Started study drug-free period (2 weeks) | 7 | 9 | 7 | 0 | 0 | 0 |
| Started transition period (2 weeks) | 133 | 139 | 137 | 0 | 0 | 0 |
| Completed | 138 | 147 | 140 | 0 | 0 | 0 |
| Not completed | 11 | 5 | 8 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 4 | 5 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn by subject due to concern on ae | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subjects were able to never take a study drug | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 64 | 68 | 74 |
| Completed | 0 | 0 | 0 | 60 | 67 | 68 |
| Not completed | 0 | 0 | 0 | 4 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Patient not keen to continue open label | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Patient non compliant to open label study drug | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Subject enrolled to compassionate use program | 0 | 0 | 0 | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
| percentage of participants | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 58.4 | 57.0 | 60.1 | 26.6 | 19.1 | 23.0 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
| percentage of participants | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal | 4.7 | 2.6 | 3.4 | 0 | 0 | 0 |
Serious Adverse event (SAE) was defined as any events which: • results in death, • is life-threatening threatening (note that this did not include a reaction that might have caused death had it occurred in a more severe form.), •results in significant or persistent disability/incapacity, • results in a congenital anomaly/birth defect (including that occurring in a fetus), • results in Important medical event that, based upon appropriate medical judgment, may jeopardize the participant and might require medical or surgical intervention to prevent 1 of the other outcomes listed here, and • results in initial inpatient hospitalization or prolongation of hospitalization. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.
| percentage of participants | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) | 0.7 | 1.3 | 2.7 | 4.7 | 0 | 2.7 |
According to International League Against Epilepsy (ILAE) classification (1981), seizures were classified as type IA (IA1, IA2, IA3, and IA4), IB, IC, II (IIA, IIB, IIC, IID, IIE, and IIF) or III. 28 day adjusted seizure frequency for partial seizures (seizure types IA+IB+IC) was calculated for treatment period by dividing the number of partial seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.
| seizures per 28 days | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period | 7.17 (1.0 to 317.0) | 5.93 (0.0 to 123.7) | 4.19 (0.0 to 269.4) |
Responders were those participants with at least 50% reduction from Baseline to the 12-week Treatment Period in partial seizure frequency per 28 days. 50% Responder rate was calculated for treatment period by dividing the number of 50% responders by the number of participants in the analysis set and multiplying the resulting value by 100.
| percentage of responders | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| 50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period | 19.0 (13.0 to 26.3) | 41.1 (33.1 to 49.3) | 49.3 (41.0 to 57.7) |
Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency, and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline to the Treatment Period.
| percent change | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period | 21.3 (-123 to 87) | 38.9 (-233 to 100) | 46.7 (-1097 to 100) |
The percentage of participants within each of the following categories of percent change in partial seizure frequency from Baseline to the Treatment Period were summarized for each treatment group: 100%, 75% to less than 100%, 50% to less than 75%, 25% to less than 50%, -25% to less than 25%, and less than -25%. Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency.
| percentage of participants | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| 100% | 0 | 5.3 | 7.4 |
| 75% to less than 100% | 3.4 | 14.6 | 17.6 |
| 50% to less than 75% | 15.6 | 21.2 | 24.3 |
| 25% to less than 50% | 27.2 | 16.6 | 20.9 |
| -25% to less than 25% | 42.9 | 31.1 | 18.2 |
| less than-25% | 10.9 | 11.3 | 11.5 |
There were three types of epileptic seizures: Partial epileptic seizures (Type I), Generalized epileptic seizures (Type II) and unclassified epileptic seizures (Type III). 28 day adjusted seizure frequency for all seizure types was calculated for treatment period by dividing the number of targeted seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.
| seizures per 28 days | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period | 7.17 (1.0 to 317.0) | 5.93 (0.0 to 123.7) | 4.19 (0.0 to 269.4) |
Participants were defined as seizure free, if they did not have missing diary days and no reported seizures during the Treatment Period.
| percentage of participants | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| All epileptic seizures | 0 | 4.6 | 6.8 |
| Partial onset seizures | 0 | 4.6 | 6.8 |
The evaluation of time to 1st partial seizure was based on the relative day of occurrence of the 1st partial seizure during the Treatment Period.
| days | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| Time to 1st Partial Seizure During the 12-week Treatment Period | 3 (2 to 3) | 5 (3 to 6) | 6 (5 to 8) |
The evaluation of time to 5th partial seizure was based on the relative day of occurrence of the 5th partial seizure during the Treatment Period.
| days | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| Time to 5th Partial Seizure During the 12-week Treatment Period | 17 (15 to 21) | 28 (23 to 36) | 32 (29 to 38) |
The evaluation of time to 10th partial seizure was based on the relative day of occurrence of the 10th partial seizure during the Treatment Period.
| days | Placebo | BRV 50 mg/Day | BRV 200 mg/Day |
|---|---|---|---|
| Time to 10th Partial Seizure During the 12-week Treatment Period | 43 (32 to 52) | 59 (48 to 76) | 69 (59 to NA) |
Blood samples were collected at indicated time points for the 50mg/day and 200mg/day groups to determine the brivaracetam plasma concentration. Participants of arm 'BRV 200 mg/day' received BRV 200 mg/day until Week 12 only and 150 mg/day during the Transition Period at Week 14. Therefore, the data is reported according to the dosage information at specified time point. As per planned analysis, one blood sample was collected for BRV plasma levels during each dosing interval between 0 to 4 hours, 4 to 8 hours, and 8 to 12 hours postdose.
| microgram/ millilitre (ug/mL) | BRV 50 mg/Day | BRV 200 mg/Day | BRV 150 mg/Day |
|---|---|---|---|
| Week 2: > 0 - 4 hours | 0.68556 ± 95.6 | 3.4340 ± 42.5 | — |
| Week 2: > 4 - 8 hours | 0.66523 ± 38.6 | 2.0615 ± 334.4 | — |
| Week 2: > 8 hours | 0.18427 ± 979.4 | 1.2144 ± 100.1 | — |
| Week 4: > 0 - 4 hours | 0.75902 ± 88.8 | 3.0038 ± 120.2 | — |
| Week 4: > 4 - 8 hours | 0.64781 ± 39.2 | 2.8516 ± 43.2 | — |
| Week 4: > 8 hours | 0.39652 ± 54.7 | 1.1054 ± 74.4 | — |
| Week 8: > 0 - 4 hours | 0.76942 ± 87.3 | 2.9983 ± 127.7 | — |
| Week 8: > 4 - 8 hours | 0.76172 ± 34.0 | 2.7030 ± 54.9 | — |
| Week 8: > 8 hours | 0.27840 ± 10.9 | 1.5590 ± 67.7 | — |
| Week 12: > 0 - 4 hours | 0.77400 ± 89.5 | 3.2508 ± 121.1 | — |
| Week 12: > 4 - 8 hours | 0.65274 ± 39.4 | 1.6017 ± 838.9 | — |
| Week 12: > 8 hours | 0.18229 ± 579.5 | 1.5001 ± 45.4 | — |
| Week 14 (Transition): > 0 - 4 hours | 0.75949 ± 85.3 | — | 2.4989 ± 54.8 |
| Week 14 (Transition): > 4 - 8 hours | 0.75692 ± 34.6 | — | 1.4383 ± 309.5 |
| Week 14 (Transition): > 8 hours | 0.41286 ± 66.4 | — | 0.82681 ± 30.6 |
Collected over From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (Up to 4 Years 10 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/149 (0%) | 1/149 (0.7%) | 39/149 (26.2%) |
| BRV 50 mg/Day | 1/151 (0.7%) | 2/151 (1.3%) | 42/151 (27.8%) |
| BRV 200 mg/Day | 0/148 (0%) | 4/148 (2.7%) | 54/148 (36.5%) |
| Placebo to OLTP BRV | 0/64 (0%) | 3/64 (4.7%) | 3/64 (4.7%) |
| BRV 50 mg/Day to OLTP BRV | 0/68 (0%) | 0/68 (0%) | 4/68 (5.9%) |
| BRV 200 mg/Day to OLTP BRV | 0/74 (0%) | 2/74 (2.7%) | 4/74 (5.4%) |
| Event | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/149 | 0/151 | 0/148 | 2/64 | 0/68 | 0/74 |
| Near drowningInjury, poisoning and procedural complications | 0/149 | 0/151 | 0/148 | 1/64 | 0/68 | 0/74 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/149 | 0/151 | 0/148 | 1/64 | 0/68 | 0/74 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/149 | 0/151 | 0/148 | 1/64 | 0/68 | 0/74 |
| ConcussionInjury, poisoning and procedural complications | 0/149 | 0/151 | 0/148 | 1/64 | 0/68 | 1/74 |
| HyponatraemiaMetabolism and nutrition disorders | 0/149 | 0/151 | 0/148 | 0/64 | 0/68 | 1/74 |
| Cervicogenic headacheNervous system disorders | 0/149 | 0/151 | 0/148 | 0/64 | 0/68 | 1/74 |
| DizzinessNervous system disorders | 0/149 | 0/151 | 0/148 | 0/64 | 0/68 | 1/74 |
| Large intestine polypGastrointestinal disorders | 0/149 | 0/151 | 1/148 | 0/64 | 0/68 | 0/74 |
| PyrexiaGeneral disorders | 0/149 | 0/151 | 1/148 | 0/64 | 0/68 | 0/74 |
| Event | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Placebo to OLTP BRV | BRV 50 mg/Day to OLTP BRV | BRV 200 mg/Day to OLTP BRV |
|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 12/149 | 15/151 | 28/148 | 0/64 | 0/68 | 0/74 |
| DizzinessNervous system disorders | 6/149 | 17/151 | 21/148 | 0/64 | 0/68 | 0/74 |
| HeadacheNervous system disorders | 11/149 | 11/151 | 7/148 | 0/64 | 0/68 | 0/74 |
| NasopharyngitisInfections and infestations | 10/149 | 7/151 | 10/148 | 3/64 | 4/68 | 4/74 |
| Upper respiratory tract infectionInfections and infestations | 7/149 | 10/151 | 8/148 | 0/64 | 0/68 | 0/74 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants who were randomized to investigational medicinal product (IMP).
| Age, Categorical(Participants) | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Total |
|---|---|---|---|---|
| <=18 years | 9 | 14 | 8 | 31 |
| Between 18 and 65 years | 137 | 135 | 138 | 410 |
| >=65 years | 3 | 3 | 2 | 8 |
| Age, Continuous(years) | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Total |
|---|---|---|---|---|
| Mean | 34.5 ± 13.2 | 33.7 ± 12.6 | 35.2 ± 13.2 | 34.5 ± 13.0 |
| Sex: Female, Male(Participants) | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Total |
|---|---|---|---|---|
| Female | 82 | 77 | 83 | 242 |
| Male | 67 | 75 | 65 | 207 |
| Race/Ethnicity, Customized(Participants) | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Total |
|---|---|---|---|---|
| Asian | 149 | 152 | 148 | 449 |
| Race/Ethnicity, Customized(Participants) | Placebo | BRV 50 mg/Day | BRV 200 mg/Day | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 148 | 151 | 147 | 446 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · vivli.org
Ran from Aug 2017 to primary completion in Jun 2022, 58 months.
Results were first posted in Nov 2023, 1 year 4 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 58 months is above that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam